OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates

This quarterly report represents an earnings surprise of -20%. A quarter ago, it was expected that this specialty pharmaceutical company would post a loss of $0.10 per share when it actually produced a loss of$0.09, delivering a surprise of 10%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. OptiNose, which belongs to the Zacks Medical - Drugs industry, posted revenues of $14.88 million for the quarter ended March 2024, surpassing the Zacks Consensus Estimate by ...